Saturday, May 31, 2025
27.3 C
Bengaluru

7 Transitions in Leadership for Indian Pharma Leaders

The rapid pace of change, which began in 2020 is unrelenting and ongoing. The high-stakes game has made many pharma leaders play defensive, instead of using the crisis to bring in the much-needed transformational changes.

Leaders continue to rely on the traditional time-tested strategies, so that they can avoid the embarrassment of ‘losing’ in this high-stakes game. Most prefer to keep doing something they know to do well. We all like to do what we are good at, and are comfortable with. Most leaders are happy to be ‘nest-building’ and remain in their comfort zones.

There are several research findings, suggesting that to make the transition successfully, leaders must navigate a tricky set of changes in their leadership focus and skills.

Here are the seven shifts that leaders must understand and adapt:

  1. Move from, Specialist to Generalist
  2. Analyst to Integrator
  3. Tactician to Strategist
  4. Bricklayer to Architect
  5. Problem solver to Agenda setter
  6. Warrior to Diplomat, and 
  7. Supporting cast member to the Lead role

Digital Excellence Pharma Academy – DEPA, a joint initiative of CredoWeb and MedicinMan has put together 4 learning modules that will enable pharma professionals to be successful in the New Normal.

Register now on https://www.credoweb.in/discussion/588/7-role-transitions-for-pharma-leaders-key-lessons-from-sanjiv-navangul to listen Deep Bhandari explain the 7 Transitions in Leaders and the Key Lessons from Sanjiv Navangul’s session.

Hot this week

Semaglutide – More Than Just a Patent Battle

The Delhi High Court has restrained Dr. Reddy’s and...

Novo Nordisk — Septerna’s $2.2 Billion Deal

A New Era for Obesity Pills Novo Nordisk has announced...

Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?

Tata 1mg App Business Model: How does it work...

GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug

In a bold move to strengthen its hepatology pipeline,...

Indian Pharma Market Performance – April 2025

The Indian Pharmaceutical Market (IPM) maintained moderate growth in...

Topics

Semaglutide – More Than Just a Patent Battle

The Delhi High Court has restrained Dr. Reddy’s and...

Novo Nordisk — Septerna’s $2.2 Billion Deal

A New Era for Obesity Pills Novo Nordisk has announced...

GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug

In a bold move to strengthen its hepatology pipeline,...

Indian Pharma Market Performance – April 2025

The Indian Pharmaceutical Market (IPM) maintained moderate growth in...

The Future in Your Palm+Chemistry – Palmistry

The future in your palm - a non-contact wearable...

Nimesulide – Nice or Not Nise?

Nimesulide Regulatory Status Worldwide Nimesulide is a non-steroidal anti-inflammatory drug...

MedicinMan Pharma Monitor March 2025

Indian Pharma Top Brands, Therapy & Regional Insights 🏆...
spot_img

Related Articles

spot_imgspot_img